Skip to content
Reipet – Lifestyle
Author:
Monopar Therapeutics Inc.
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
July 22, 2026
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
July 20, 2026
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
June 30, 2026
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
June 26, 2026
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
June 1, 2026
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
May 19, 2026
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 14, 2026
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
April 19, 2026
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
March 27, 2026